Literature DB >> 19158196

Cortisol inactivation by 11beta-hydroxysteroid dehydrogenase-2 may enhance endometrial angiogenesis via reduced thrombospondin-1 in heavy menstruation.

Mick Rae1, Amirah Mohamad, Deborah Price, Patrick W F Hadoke, Brian R Walker, J Ian Mason, Stephen G Hillier, Hilary O D Critchley.   

Abstract

CONTEXT: Heavy menstrual bleeding (HMB; menorrhagia) impairs quality of life for women and requires medication or surgery. Because glucocorticoids inhibit angiogenesis in other organs, we hypothesized that endometrium of women with HMB is subject to decreased local glucocorticoid exposure and enhanced angiogenesis, thereby increasing menstrual bleeding.
DESIGN: Endometrium was collected from 29 women with menstrual complaints. Menstrual blood loss was measured by alkaline-hematin assay (n = 12, > 80 ml (HMB); n = 17, < 80 ml). Quantitative RT-PCR for thrombospondin-1 (TSP-1) and glucocorticoid-metabolizing enzymes, 11beta-hydroxysteroid dehydrogenases-1 and -2 (11betaHSD1,2) was performed. Glucocorticoid effects on endometrial stromal cells and uterine endothelial cells (UECs) were determined. RNA interference studies in UECs examined the effect of TSP-1 ablation on cortisol action.
RESULTS: Secretory phase endometrium mRNA levels for the cortisol inactivating enzyme 11betaHSD2 were higher [3.78 +/- 1.29 vs. 1.40 +/- 0.6 (arbitrary units), P < 0.05], whereas TSP-1 mRNA was lower [0.40 +/- 0.13 vs. 1.66 +/- 1.02 (arbitrary units), P < 0.05] in women with HMB. In cultured endometrial stromal cells and UECs, cortisol increased TSP-1 expression. Both cortisol and TSP-1 inhibited new vessel formation in endometrial explants embedded in Matrigel. In UECs cortisol inhibition of tube-like structure formation was blocked by small interfering RNA (siRNA) against TSP-1 (25 +/- 2.5% cortisol inhibition with scrambled siRNA vs. 0% cortisol inhibition with TSP-1 siRNA inactivation, P<0.01).
CONCLUSIONS: Enhanced inactivation of cortisol by 11betaHSD2 in endometrium from women with HMB may explain reduced TSP-1 levels and hence endothelial cell dysfunction and abnormal angiogenesis. Inhibition of 11betaHSD2 may be a rational novel therapy for heavy menstrual bleeding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158196     DOI: 10.1210/jc.2008-1879

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.

Authors:  Ping Yang; Shan Lv; Yan Wang; Yi Peng; Zixing Ye; Zhuying Xia; Guoxian Ding; Xu Cao; Janet L Crane
Journal:  Bone       Date:  2018-05-23       Impact factor: 4.398

2.  Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11.

Authors:  Kinza Younas; Marcos Quintela; Samantha Thomas; Jetzabel Garcia-Parra; Lauren Blake; Helen Whiteland; Adnan Bunkheila; Lewis W Francis; Lavinia Margarit; Deyarina Gonzalez; R Steven Conlan
Journal:  J Mol Med (Berl)       Date:  2019-06-29       Impact factor: 4.599

Review 3.  Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity.

Authors:  Robert S Weinstein
Journal:  Bone       Date:  2009-07-08       Impact factor: 4.398

4.  The Plasminogen Activator System, Glucocorticoid, and Mineralocorticoid Receptors in the Primate Endometrium During Artificial Menstrual Cycles.

Authors:  Esra Demirel; Reem Sabouni; Neelima Chandra; Ov D Slayden; David F Archer
Journal:  Reprod Sci       Date:  2021-11-18       Impact factor: 3.060

Review 5.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

6.  Glucocorticoid-mediated inhibition of angiogenic changes in human endothelial cells is not caused by reductions in cell proliferation or migration.

Authors:  James J Logie; Sadaf Ali; Kathryn M Marshall; Margarete M S Heck; Brian R Walker; Patrick W F Hadoke
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

7.  Low-dose dexamethasone as a treatment for women with heavy menstrual bleeding: protocol for response-adaptive randomised placebo-controlled dose-finding parallel group trial (DexFEM).

Authors:  P Warner; C J Weir; C H Hansen; A Douglas; M Madhra; S G Hillier; P T K Saunders; J P Iredale; S Semple; B R Walker; H O D Critchley
Journal:  BMJ Open       Date:  2015-01-14       Impact factor: 2.692

Review 8.  Steroid regulation of menstrual bleeding and endometrial repair.

Authors:  Jacqueline A Maybin; Hilary O D Critchley
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

Review 9.  Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation.

Authors:  Patrick W F Hadoke; Tiina Kipari; Jonathan R Seckl; Karen E Chapman
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

Review 10.  Menstrual physiology: implications for endometrial pathology and beyond.

Authors:  Jacqueline A Maybin; Hilary O D Critchley
Journal:  Hum Reprod Update       Date:  2015-08-07       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.